U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H37N3O3S3.ClH
Molecular Weight 596.268
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLOBALAGLIATIN HYDROCHLORIDE

SMILES

Cl.O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6

InChI

InChIKey=FRUQQNDJVRDIRH-JOFLZTHPSA-N
InChI=1S/C28H37N3O3S3.ClH/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23;/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32);1H/t24-,28-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C28H37N3O3S3
Molecular Weight 559.807
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27163171

LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM. Eli Lilly is developing LY 2608204 as an orally administered, once-daily therapy for type 2 diabetes. LY-2608204 is in phase I clinical trials for the treatment of type 2 diabetes.

Originator

Eli Lilly
239
Curator's Comment: # Eli Lilly

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1447
 42.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
342 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
240 mg 1 times / day steady-state, oral
dose: 240 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
471.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
320 mg 1 times / day steady-state, oral
dose: 320 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
29.36 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
183.88 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
160 mg 1 times / day steady-state, oral
dose: 160 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
69.43 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6028.2 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
240 mg 1 times / day steady-state, oral
dose: 240 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9218.38 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
320 mg 1 times / day steady-state, oral
dose: 320 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
369.71 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3036.75 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
160 mg 1 times / day steady-state, oral
dose: 160 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1009.35 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33125674/
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LY-2608204 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Generation of stem cell-derived β-cells from patients with type 1 diabetes.
2016-05-10
Patents

Patents

US8063079
2

Sample Use Guides

In Vivo Use Guide
Oral capsules of LY2608204 given once daily at a starting dose of 160mg, which may be titrated in 3 dose escalations to 240mg, 320mg and 400mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
Route of Administration: Oral
In Vitro Use Guide
Treatment with 1uM of LY2608204 increases insulin release in T1D and ND SC-β cell lines at both low- and high-glucose challenges compared with control by a factor of 2.0 on average.
Substance Class Chemical
Created
by admin
on Wed Apr 02 10:12:37 GMT 2025
Edited
by admin
on Wed Apr 02 10:12:37 GMT 2025
Record UNII
CH9BD8J28R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLOBALAGLIATIN HYDROCHLORIDE
Common Name English
LY2608204 HYDROCHLORIDE
Preferred Name English
SY-004 HYDROCHLORIDE
Code English
2-CYCLOHEXYL-1-(4-(CYCLOPROPYLSULFONYL)PHENYL)-N-(5-((2-(1-PYRROLIDINYL)ETHYL)THIO)-2-THIAZOLYL)-, HYDROCHLORIDE (1:1), (1R,2S)-
Systematic Name English
LY-2608204 HYDROCHLORIDE
Code English
Globalagliatin hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
162623518
Created by admin on Wed Apr 02 10:12:37 GMT 2025 , Edited by admin on Wed Apr 02 10:12:37 GMT 2025
PRIMARY
FDA UNII
CH9BD8J28R
Created by admin on Wed Apr 02 10:12:37 GMT 2025 , Edited by admin on Wed Apr 02 10:12:37 GMT 2025
PRIMARY
Related Record Type Details
Structure of GLOBALAGLIATIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of GLOBALAGLIATIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966